Abstract : In case of failure of metformin monotherapy, several pharmacological strategies may be considered for the treatment of type 2 diabetes. Among these, the addition of an inhibitor of the dipeptidyl peptidase-4 (dpp-4) enzyme, a medication commonly named as gliptin, is increasingly used because of two main advantages over sulfonylureas, i.e. the absence of both hypoglycaemia and weight gain. The combination of a gliptin and metformin further improves glycaemic control compared to either monotherapy, due to complementary mechanisms of action. Most patients with type 2 diabetes are treated every day with numerous drugs because of the presence of comorbidities so that poor drug compliance is a major concern in such a population. The use of fixed-dose combinations (fdcs) may improve compliance and, therefore, several gliptin-metformin fdcs are now available. The most recent one is Jentadueto®, which combines linagliptin, a selective dpp-4 inhibitor without renal excretion, and metformin, the first-line antidiabetic compound. This fdc is commercialized with two dosages of metformin, i.e. 2.5 mg linagliptin/850 mg metformin and 2.5 mg linagliptin/1.000 mg metformin, and should be administered twice daily with meal. While linagliptin may be prescribed whatever the renal function, the use of fdc should take into account classical restrictions imposed by the presence of metformin.